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Cardiovascular diseases are the ﬁrst leading cause of death and morbidity in developed countries. The use of animal models have
contributed to increase our knowledge, providing new approaches focused to improve the diagnostic and the treatment of these
pathologies.Severalmodelshavebeen developed toaddress cardiovascularcomplications,includingatherothromboticandcardiac
diseases, and the same pathology have been successfully recreated in diﬀerent species, including small and big animal models of
disease. However, genetic and environmental factors play a signiﬁcant role in cardiovascular pathophysiology, making diﬃcult
to match a particular disease, with a single experimental model. Therefore, no exclusive method perfectly recreates the human
complication, and depending on the model, additional considerations of cost, infrastructure, and the requirement for specialized
personnel,shouldalsohaveinmind.Consideringallthesefacts,anddependingonthebudgets available,modelsshouldbeselected
thatbest reproduce the diseasebeing investigated. Here we willdescribe modelsofatherothromboticdiseases,includingexpanding
and occlusive animal models, as well as models of heart failure. Given the wide range of models available, today it is possible to
devise the best strategy, which may help us to ﬁnd more eﬃcient and reliable solutions against human cardiovascular diseases.
1.Introduction
Cardiovascular diseases are the ﬁrst leading cause of death
and morbidity in developed countries. Cardiac and vascular
complications are complex multifactorial pathologies, in
which both genetic and environmental factors are impli-
cated, thus making them very diﬃcult to prevent. The
development of animal models of cardiovascular disease
(CVD), including cardiac and atherothrombotic diseases,
has provided us today with important insights into the
pathophysiology,and they were found to be essential tools to
evaluate new therapeutic strategies to predict and to prevent
these complications.
Here, we will summarize the most common models
of cardiovascular diseases, including those implemented in
both large and small animals, designed for helping to cover
with more precision and to better understand every single
aspect related to these human pathologies. In particular, we
will describe models of atherothrombotic diseases, including
expanding abdominal aortic aneurysms (AAA), thoracic
aneurysms, and occlusive atherosclerotic diseases, as well as
models of heart failure. These situations constitute today
a signiﬁcant challenge since predictors to evaluate early
detection and forecast progression are crucial in these
pathologies, yet they are poorly explored.
2.Animal ModelsofAtherothromboticDisease
2.1. Mouse Models. Atherosclerosis is a complex multifac-
torial disease with diﬀerent etiologies that synergistically
promote lesion development. Mouse models have proved
to be useful to study development and progression of
atherosclerotic lesion, and several reviews have extensively
discussed the diﬀerent available models [1–3]. In particular,2 Journal of Biomedicine and Biotechnology
knockout and transgenic mouse models for atherosclerosis
have been instrumental in understanding the molecular and
cellular mechanisms involved in atherogenesis, and in eval-
uating the eﬀectiveness of new and existing atherosclerotic
drugs [4].
As wild-type mice are resistant to lesion develop-
ment, the current mouse models for atherosclerosis are
based on genetic modiﬁcations of lipoprotein metabolism
with additional dietary changes. Among them, low-density
lipoprotein receptor-deﬁcient mice (LDLR−/− mice) and
apolipoprotein E-deﬁcient mice (apoE−/− mice) are the
most widely used. Atherosclerotic lesions seen in these
models can be exacerbated by the addition of risk factors
such as hypertension or diabetes. Mice have become widely
used as models of human atherosclerosis as they oﬀer
advantage compared with other species (Table 1).
2.2. LDLR−/− Mice. The LDLR−/− mouse represents a
model of familial hypercholesterolemia due to one of the
mutations aﬀecting the LDLR, and the plasma lipoprotein
proﬁle resembles that of humans. Mice, which are genet-
ically deﬁcient in LDLR manifested delayed clearance of
VLDL and LDL from plasma. As a result, LDLR−/− mice
exhibit a moderate increase of plasma cholesterol level and
develop atherosclerosis slowly on normal chow diet [5, 6].
Interestingly, the severity of the hypercholesterolemia and
atherosclerotic lesions in LDLR−/− mice can be accelerated
by feeding a high-fat, high-cholesterol diet [5–7], by mutat-
ing the apoB gene into an uneditable version [8, 9], and
by crossing either with leptin-deﬁcient mice [10]o rw i t h
apoB100 transgenic mice [11]. Under these conditions, the
lesions in the aorta can progress beyond the foam-cell fatty-
streak stage to the ﬁbroproliferative intermediate stage.
In addition to LDLR−/− mice, the LDLR and apoE
double-deﬁcient mouse (LDLR−/−apoE−/−)w h i c hd e v e l -
ops severe hyperlipidemia and atherosclerosis even on
a regular chow diet, has been proposed as a suitable
model to study the antiatherosclerotic eﬀect of compounds
without having to feed the animals an atherogenic diet
[12, 13]. However, the response of both LDLR−/− and
LDLR−/−apoE−/− mice to the treatment with hypolipi-
demic drugs varies from lowering of plasma cholesterol
without atherosclerosis decrease to a weak lesion reduction
withorwithoutlowerplasma cholesterol[4,14].Bycontrast,
those mice eﬀectively respond to agonists of peroxisome
proliferator-activated receptor (PPAR) or liver X receptor
[15, 16]. This great variability indicates that LDLR−/−
is probably not well-suited for analyzing the cholesterol-
lowering and antiatherogenic eﬀects of drugs.
2.3. ApoE−/−Mice. In 1992 two diﬀerentgroups simultane-
ously generated the apoE−/− mice by homologous recom-
bination in embryonic stem cells [17, 18]. Homozygous
deﬁciency in apoE gene results in a marked increase in the
plasma levels of LDL and VLDL due to a failure in their
clearancethrough the LDLR and LDLR-related proteins. The
apoE−/− mouse contains the entire spectrum of lesions
observedduringatherogenesisandwastheﬁrstmousemodel
described to develop lesions similar to those of human [17,
18].
Under normal dietary conditions, apoE−/− mice have
dramatically elevated plasma levels of cholesterol, and they
develop extensive atherosclerotic lesions widely distributed
throughout the aorta [18–20]. This process can be exacer-
b a t e do nah i g h - f a td i e t ,w i t hf e m a l em i c em o r es u s c e p t i b l e
than male mice [19]. A chronological analysis of atheroscle-
rotic lesions in apoE−/− mice revealed that the sequential
events involved in lesion formation in this model are strik-
inglysimilar tothoseinlargeranimalmodelsandinhumans.
Predilection sites for atherosclerotic lesions in apoE−/−
mice are the aortic root, followed by the aortic arch, the
brachiocephalic trunk, the left carotid, and subclavian and
coronary arteries [6, 21]. Aortic lesions rapidly developfrom
initial fatty streaks comprised primarily of foam cells with
migrating smooth muscle cells to more complex lesions in
middle-agedmice.Theseadvancedlesionsareheterogeneous
but typically composed of a necrotic core surrounded by
proliferating smooth muscle cells and extracellular matrix
proteins [20, 22].
The apoE−/− mice are currentlythe most widely utilized
animal model for the study of atherosclerosis. In fact, the
eﬀect of many genes on the development of atherosclerosis
has been examined by crossing the apoE−/− mice with other
geneticallymanipulated animals. Furthermore,the apoE−/−
mouse serves as a useful tool to: (i) identify atherosclerosis-
susceptibility-modifying genes, by the candidate-gene and
gene-mapping methods, (ii) decipher molecular mechanism
and cell types involved in atherogenesis, (iii) search into
the drug eﬀects on atherosclerosis, and (iv) assess novel
therapies that prevent lesion progression. In this sense,
the apoE−/− mouse model was used to test additional
therapeutic eﬀects of statins beyond those attributable
solely to cholesterollowering. One of the ﬁrst observations
was the paradoxical eﬀect of simvastatin on atherogenesis
in both apoE−/− and LDLR−/− mice [23]. In contrast
to the atheroprotective eﬀect of simvastatin in LDLR−/−
mice, age-matched apoE−/− showed elevated serum total
cholesterol and increased aortic plaque area, thus suggesting
that the therapeutic eﬀect of simvastatin may depend on
t h ep r e s e n c eo faf u n c t i o n a la p o E[ 23]. In spite of this,
the antiatherosclerotic eﬀects of other statins have been
eﬀectively proven in apoE−/− mice [24, 25]. Several other
compounds, such as angiotensin II receptor antagonists or
PPAR agonists [26] also reduced the extent and severity of
atherosclerotic lesions without lowering plasma cholesterol
in apoE−/− m i c e .H o w e v e r ,t h er e c e n tﬁ n d i n go fi n c r e a s e d
atherogenesis in apoE−/− mice treated with PPAR alpha and
PPAR gamma agonists is consistent with clinical ﬁndings of
the adverse cardiovascular events of dual therapy [27].
Nevertheless, a major limitation of the apoE−/− mouse
model is the infrequency of plaque rupture and thrombo-
sis, two common complications of human atherosclerosis.
Ischemic cardiomyopathy has been occasionally found in
aged mice [20], but interestingly, rapid coronary artery
occlusion, myocardial infarction, and even premature death
occur when apoE−/− mice were crossed with mice deﬁcient
in scavenger receptor class B type I or its adaptor proteinJournal of Biomedicine and Biotechnology 3
Table 1: Animal models of atherosclerosis:advantages and limitations.
Mouse
(i) Rapid development of atherosclerotic plaques (i) Only partial resemblance to humans
(ii) Short reproductive cycle (ii) More atherosclerotic than atherothrombosis model
(iii) Large litters (iii) Very high levels of blood lipids
(iv) Well-known genome
(v) Relative ease of genome manipulation
(vi) Relatively cheap
(vii) Useful for noninvasive imaging
( M R I ,P E T ,C T ,u l t r a s o u n d )
(viii) Large experience
Rat
(i) Easy, available, and cheap (i) Do not develop atheroma
(ii) Useful for restenosis analysis
Rabbit
(i) Medium size (i) Need for high blood cholesterol levels
(ii) Fibroatheroma lesions (ii) No plaque rupture model
(iii) Useful for restenosis models (iii) A model of neointima formation rather than
atherosclerosis
(iv) Aﬀordable
Porcine
(i) Lesions more similarto human disease (i) High cost
(ii) Valid for restenosis studies (ii) Diﬃcult handling
(iii) Few genomic tools
[28, 29], thus mimicking many cardinal features of human
coronary heart disease.
2.4. Transgenic Mice. Transgenic technologies have provided
a series of very useful mouse models to study hyperlipi-
demia and atherosclerosis. Among them, mice expressing
mutant forms of apoE, such as apoE3Leiden (E3L) and
apoE (Arg 112→Cys→142) transgenic mice, are the more
widely studied. These mice display a lipoprotein proﬁle
comparable to that of patients with dysbetalipoproteinemia,
inwhich plasma totalcholesterolandtriglyceridesare mainly
conﬁned to (V) LDL [30]. The E3L transgenic mice develop
atherosclerotic lesions with all the characteristics of human
vasculopathy, varying from fatty streak to mild, moderate,
and severe plaques [30, 31]. Furthermore, E3L transgenic
mice and the more recently developed E3L/Cholesteryl ester
transfer protein (CETP) transgenic mice have been shown
to be more sensitive to a variety of hypolipidemic drugs and
PPAR agonists than apoE−/− and LDLR−/− mice [4, 32].
2.5. Mouse Models of Diabetes-Accelerated Atherosclerosis.
Diabetes is a high risk factor of cardiovascular disease.
The cardiovascular complications of diabetes are manifested
primarily as ischemic heart disease caused by accelerated
atherosclerosis, and also as cardiomyopathy. Several models
are available to study atherosclerosis and cardiomyopathy
associated with diabetes, including apoE−/− and LDLR −/−
mice in which type 1 diabetes is induced by streptozotocin
or viral injection [33, 34]. In both mice, diabetes induc-
tion did not markedly change plasma lipid levels, thereby
mimicking the accelerated atherosclerosis seen in patients
with type 1 diabetes. Importantly, streptozotocin-injected
atherosclerotic mice exhibited increased atherosclerosis in
the aortic sinus, carotid artery, and abdominal aorta, as well
as calciﬁcations in the proximal aorta [34, 35].
In brief, mouse models have been very useful to unveil
the importance of inﬂammatory and immunological mecha-
nisms in the formation and progression of atheroma plaque.
Recently, an enormous interest for the use of noninvasive
magnetic resonance imaging (MRI) in mouse models of
atherosclerosis has arisen [36], since MRI accurately char-
acterizes the location, the size and the shape of lesions.
In addition, MRI allows the diﬀerentiation between ﬁbrous
and lipid components of regress in plaques in mice. In
combination with noninvasive imaging technologies, mouse
models of atherosclerosis today also serve to test novel4 Journal of Biomedicine and Biotechnology
contrast agents, and to design and target speciﬁc molecules
involved in high-risk plaque.
2.6. Rabbit Models. The high-cholesterol diet rabbit model
has been widely used for experimental atherosclerosis. Back
in 1913, cholesterol was found to cause atherosclerotic
changes in the rabbit arterial intima, which is very similar to
human atherosclerosis. Atherosclerotic lesions also develop
in normolipemic rabbits as a result of repeated, or con-
tinuous intimal injury by an indwelling aortic polyethylene
catheter, balloon angioplasty or nitrogen exposure. There-
fore, many studies have used the rabbit model with high-
cholesterol diet, arterial wall injury, or, most commonly, a
combination of these two methods. In all these models, the
observed lesions resemble, at least in part, those seen in
human plaques, mainly regarding the inﬂammatory compo-
nent, though the vascular smooth muscle cell proliferation
determines for a great deal the lesion.
The rabbit model has largely been used to study the
inﬂuence of lipid lowering (by diet or statins) on the
plaque formation and “stabilization.” Those studies have
contributed to unveil the mechanisms by which lipid lower-
ing reduces macrophage accumulation and other aspects of
atheroma inﬂammation [37, 38].
Recently, we have set up a novel rabbit model to examine
theinﬂuence ofinﬂammation on atheroscleroticplaque.The
aim was to study some mechanisms by which atherosclerosis
is particularly severe in patients with rheumatoid arthritis.
Brieﬂy,themodelconsistsinacombinationoffemoralinjury
in hyperlipidemic rabbits and induced acute knee arthritis.
Those animals had more intensive vascular lesions than
animals without inﬂammation. This model could represent
a novel approach to the study, inﬂammation-associated
atherosclerosis [39].
A model for plaque rupture has been also developed
in rabbits. Shimizu and coworkers [40] have developed a
simple rabbit model of vulnerable atherosclerotic plaque,
with thecombinationof aggressive vascular injury associated
to a hyperlipidemic diet. The histological ﬁndings showed
that an aortic plaque had the three features of “vulnerable
plaque”: lipid-rich core, accumulation of macrophages, and
a thin ﬁbrous cap. In addition, a low-density lipoprotein
(LDL) receptor-deﬁcient animal model (the WHHL rabbit)
has been developed.This model resembles tohuman familial
hypercholesterolemia and shows evidence of progressive
disease of the aorta with accumulation of birefringent lipids
in intimal lesions and plaques, as well as in the media from
birth to 1 year of age.
Although rabbit aortic arteries are smaller in vessel
diameter than human carotid artery, they allows the studies
with endovascular therapeutic devices. In addition, the
rabbit model has also been used for the quantiﬁcation
of atherosclerotic aortic component by MRI. This tech-
nique accurately quantiﬁes ﬁbrotic and lipid components
of atherosclerosis in the model and may permit the serial
analysis of therapeutic strategies on atherosclerotic plaque
stabilization [41].
2.7. Porcine Models. They prevention of heart attack and
stroke depends on the detection of vulnerable plaques
and development of plaque-stabilizing therapies. Animal
models are essential for testing mechanistic hypotheses in
a controlled manner, they should be representative of a
human disease, and at the same time be easy to manip-
ulate. However, vulnerable plaque recreation is one of the
toughest tasks in animal model design. Plaque rupture is
an additional complication of an already complex process,
and the precise mechanisms involved remain hypothetical.
A plethora of experimental approaches are available for
growing atherosclerotic lesions in various animal species as
mentioned above (Table 2).
Currently, there is no single and golden standard animal
model of vulnerable plaque, but pig models are probably the
best way to recreate human plaque instability. The combina-
tion of diabetes and hypercholesterolemia constitutes a good
model of accelerated atherosclerosis [42], and it was relevant
study the role of certain biomarkers, such as the Lp-PLA2
since these animals share a similar plasma lipoprotein proﬁle
humans. In this regard, the selective inhibition of Lp-PLA2
by darapladib decreased progression to advanced coronary
atherosclerotic lesions and conﬁrmed a crucial role of vascu-
lar inﬂammation not associated to hypercholesterolemia, in
the development of lesions implicated in the pathogenesis of
myocardial infarction and stroke [43].
Several porcine models of advanced human-like coro-
nary atherosclerosis have been employed to analyze the
development and validation of coronary imaging technolo-
gies. In the evolving era of technological development, the
availability and use of such animal models will become
critical for the development of emerging technologies in
interventional cardiology [44], and for the study of drug-
eluting stents [45]. In addition, the porcine models of
coronary atherosclerosis allow examining the impact of
adventitial neovascularisation, on atherosclerotic plaque
composition and vascular remodelling [46].
3.Animal ModelsofAbdominalAortic
Aneurysms (AAAs)
Animal models of atherothrombotic AAA are essential tools
for the preclinical evaluation of new therapeutic strategies
for the suppression of aneurysmal degeneration (Table 3).
Recent insights into the mechanisms of human AAA have
come from the studies in mouse models, and elastase-
induced AAA in particular appears to recapitulate many
features of human AAA. Here we brieﬂy outline the most
frequently used models of AAAs, and refer the reader to
recent comprehensive reviews regarding additional animal
models [47–52].
3.1. Rat Models
3.1.1. Localized Aortic Perfusion with Elastase. This model
consists of exposing a segment of the abdominal aorta and
infusing it with elastase [53]. The degradation of elastic
ﬁbers triggers an inﬂammatory response that develops intoJournal of Biomedicine and Biotechnology 5
Table 2: Animal models of plaque rupture and plaque associated thrombosis.
Spontaneous Induced
39–54-month-old pigs with inherited hyper=LDL
cholesterolemia. ApoE−/− mice after squeezing the aorta supplemented between forceps.
42–54-week old ApoE−/− mice. Hypercholesterolemic rabbits subjected to balloon injury.
Dahl salt-sensitive hypertensive transgenic rats for human
cholesteryl ester transfer protein. Atherosclerotic ApoE−/− mice subjected to photochemical injury.
— Intraperitoneal injection of Russell’s viper venom in New Zealand White
rabbits intermittently fed with high cholesterol diet.
Intraperitoneal injection of Russel’s viper venom in Watanabe heritable
hyperlipidemic rabbits, in combination with the administration of
serotonin or angiotensin II.
an aneurysm [54, 55]. The severity of the induced AAA can
be increased by adding plasmin to the infusion. This model
has been adapted for use in several other species, including
rabbit, mouse, and large animals.
3.1.2. Decellularized Xenografts. This model was based on
the observation that chronic rejection of arterial allografts
and xenografts, results in arterial wall dilatation and rupture.
Michel and coworkers decellularized a section of abdominal
aorta from one species (e.g., guinea pig), and the resulting
tube of intact extracellular matrix was grafted into another
morphologically compatible species, usually rat [58]. The
xenogenic extracellular matrix triggers the destruction of
host matrix, leading to aneurysm formation. The model has
been successfully used to evaluate therapeutic targets [64–
69],althoughtheheterogeneityoftheaneurysmsformedand
the lack of vessel rupture are signiﬁcant limitations.
3.2. Mouse Models. The mouse has become the preferred
modelforcardiovascular research for severalreasons, includ-
ing the ease of handling, low procedure costs, and the
abilitytomanipulatethemousegenome.Consequently,ofall
animal models of AAA, mouse models have provided most
of the insights into the mechanisms of human AAA. The
following models are the most widely-used to date.
3.2.1. Calcium-Chloride-Induced AAA. In this method, ini-
tially developed in rabbits [62], calcium chloride is applied
periaortically in the region between the renal arteries and
the iliac bifurcation. Signiﬁcant dilatation of the aorta is
observed within 14 days, and the severity is signiﬁcantly
increased if calcium chloride is applied together with thio-
glycolate and if animals are fed a high-cholesterol diet [56].
Unlike other models, calcium chloride application induces
AAA without the need for mechanical intervention.
3.2.2. Elastase-Induced AAA. The elastase-induced model
was adapted for mice by Pyo et al. [57]. Elastase perfusion in
mouse aorta causes a mild-to-moderate dilatation initially,
which subsequently develops to a >100% increase in aortic
diameter within 14 days. In this model, the degradation
of medial elastin is delayed, and the subsequent aortic
wall inﬂammation consists of mononuclear phagocytes
throughout the adventitial and medial layers, with relatively
few polymorphonuclear cells localized to the adventitia
[57]. Elastase-induced injury increases the expression of
MMPs, cathepsins, and other proteases [70], with MMP-9
being localized to aneurysm-inﬁltrating macrophages [71].
Elastase-induced AAAs thus appear to recapitulate many
features of human AAAs, and this model has become a
valuableandconvenienttoolforsystematicallyevaluatingthe
rolesofindividualgeneproductsinaneurysmaldegeneration
[71–80].
When compared to calcium-chloride-induced AAA, the
main limitation of this method is in the mechanical stress
required to recreate medial elastic degradation. However,
the protocol resembles the time course of events leading
to human AAA, including initial recruitment of leukocytes
and mast cells, the development of a transmural aortic
wall inﬂammatory response, and ﬁnally the upregulation of
extracellular matrix metalloproteinases and other proteases,
which induce a progressive degradation of the medial elastin
and collagen, leading to the ﬁnal aortic dilatation.
3.2.3. Angiotensin II-Induced AAA. This procedure was ini-
tially developed to deﬁne whether increased plasma concen-
trations of Angiotensin II (Ang II), have a direct eﬀecton the
atherogenic process in hyperlipidemic old apoE−/− mice.
Unexpectedly, Ang II also producedlarge suprarenal abdom-
inal aortic aneurysms in these animals [81]. In this model,
inﬂammation of the vessel wall is associated with signaling
through AT1a receptors [82], nuclear factor- (NF-) kappaB-
mediated induction of proinﬂammatory genes, including
MCP-1, M-CSF, iNOS, COX-2, inhibition of PPARs [83],
activation of the NADPH oxidase p47phox [84], c-JUN N-
terminal [85], Rho kinases [86], and enhanced recruitment
of macrophages [87, 88] and extracellular matrix compo-
nents and degrading enzymes [89–91], leading to vessel
dissection, and rupture. The severity of AAA is higher in
hyperlipidemic apoE−/− or LDLR−/− male mice (∼60%
of mice), when compared to normolipidemic C57Bl/6 mice,
although in these models neither hyperlipidemia per se nor
atherosclerosis is considered major determinants [92–94].
The model contributed to evidence the implication of
the rennin-angiotensin (RAS) system in aneurysmal disease.
However, two main limitations should be considered: the6 Journal of Biomedicine and Biotechnology
Table 3: Current procedures for inducing AAA in animals.
Species AAA models
Murine
Calcium Chloride [56].
Elastase infusion [57].
Angiotensin-II-infused AAA: used in hyperlipidemic (ApoE−/− or LDLR−/−) male mice or in wild-type C57BL/6 mice in
conjunction with repeated administration of neutralizing TGF-β antibodies [50].
Decellularized xenografts: grafting of abdominalaortic extracellular matrix from one species to a compatible recipient of a
diﬀerent species [58].
Spontaneous [59].
Rabbit Elastase-induced AAA: similar to the murine model [60], also applicable to the carotid artery [61].
Calcium chloride [62].
Pig Surgical model: dilatationof the infrarenal aorta with an angioplastyballoon followed by infusion of pancreatic porcine
elastase [63].
suprarenal location of the aneurysm (in contrast to the
infrarenal location in humans) and the clinical relevance
of RAS inhibition, since the association of RAS in human
AAA has provided controversial results, pointing towards
necessary large population studies.
3.2.4. Spontaneous Mouse Mutants. The blotchy mouse is
a mouse strain containing a spontaneous mutation on the
X chromosome which leads to abnormal intestinal copper
absorption. These animals have weak elastic tissue due to
failed crosslinking of elastin and collagen, and developaortic
aneurysms mainly in the aortic arch, thoracic aorta, and
occasionally in the abdominal aorta [59]. However, results
from this model are diﬃcult to interpret, since the mutation
produces many severe additional eﬀects.
3.3. Rabbit Models. Severalof the same interventions used in
micearealsoimplementedinrabbits,includingelastaseinfu-
sion [60] and calcium chloride application to the abdominal
aorta [56]. Another intervention used in rabbits is elastase
infusion in the right carotid artery [61]. The main advantage
of rabbits over other animal models is that rabbit aneurysms
more closely resemble human aneurysms hemodynamically
and histologically. Rabbit models also combine several of
the attractive features of small animals, such as the easy
housingandhandling.Inaddition,similarly tolargeanimals,
rabbitaneurysms can be monitored by accessing through the
femoral artery, thus providing an excellent model for testing
endovascular therapies [95, 96].
3.4. Porcine Models. Porcine models of AAA have provided
signiﬁcant information about the changes that occur after
AAAinductionandabouttheresponses tostentdeployment.
A recently-developed porcine model combines mechanical
dilatation by balloon angioplasty with enzymatic degrada-
tionbyinfusion ofacollagenase/elastasesolution.Themodel
is characterized by gradual AAA expansion associated with
degradation of aortic wall elastic ﬁbers, an inﬂammatory
cell inﬁltrate, and persistent smooth muscle cell loss [63].
A broad number of similarities were found between this
model and human AAA, and the procedure may also
represent an excellent method to evaluate endovascular
related procedures. Despite the beneﬁts, however, pigs have
signiﬁcant disadvantages, including complex animal han-
dling, the requirement of special housing and surgical room
facilities, the elevated cost of the animals, and the reduced
sample sizes per assay.
3.5. Thoracic Aortic Aneurysm (TAA). Elastic tissue degra-
dation is also related to the development of thoracic aortic
aneurysm (TAA), and mouse models have signiﬁcantly
advanced the understanding of this pathology. TAA is a
characteristic feature of Marfan syndrome (MFS), a disorder
caused by mutations that aﬀect the structure or expression
of the extracellular matrix protein ﬁbrillin-1, a glycoprotein
that is associated of extracellular proteins, including integrin
receptors and insoluble elastin [97]. Fibrillin-1 mutations
in MFS decrease ECM sequestration of latent TGFβ,t h u s
rendering it more prone to or accessible for activation [98–
100]. TAA progression in MFS is driven by elastic ﬁber cal-
ciﬁcation, vascular wall inﬂammation, intimal hyperplasia,
structural collapse of the vessel wall, impaired activation of
MAP kinase signaling, and altered synthesis of ECM proteins
and matrix-degrading enzymes (MMPs) [101]. Systemic
administration with TGFβ antagonists has been successfully
used to mitigate vascular disease in mouse models of MFS
a n di nc h i l d r e nw i t hs e v e r ea n dr a p i d l yp r o g r e s s i v eM F S[ 97,
102]. Moreover, studies in mouse models have shown that
ﬁbulin-4 and LRP1 are also associated with TAA [103, 104].
4.Animal ModelsofHeart Failure
Models of heart disease in small animals, particularly rats,
have been very useful for the assessment of pharmacolog-
ical therapies. In addition, several target genes have been
identiﬁed in genetically modiﬁed mouse models. Many of
these genes have proved to be crucial in the initiation and
progression of heart disease. Below, we describe the animal
models currently used to study heart failure, which are also
summarized in Table 4.
4.1. Rat Models. Rat models have dominated research into
heart damage because, while rats share many of the beneﬁts
of mice (low cost, ease of handling, etc.), their largerJournal of Biomedicine and Biotechnology 7
Table 4: Current procedures for inducing heart damage in animals.
Species Heart failure models
Murine
Myocardial damage
Chemical: isoproterenol administration [106].
Electrical: overlapping burns [107].
Surgical: coronaryartery ligation[105].
Ischemia Reperfusion:
Transient occlusion of the left coronary artery [108].
Cryoinfarction: cryo-injuries to the epicardium [109].
Pressure overload: aortic constriction and banding. Aortic stenosis [110, 111].
Transgenic models of dilated cardiomyopathy: mutation of cardiac α-actin protein [112].
Rabbit
Spontaneous: WHHLMI rabbits [113].
Coronary artery occlusion: similar to the murine model, also applicable to the carotid artery. This is an excellent
model for testing endovascular therapies [114].
Pressure overload: aortic banding [115], valvular stenosis [116].
Dog
Microembolization [117].
Tachycardia: ventricular pacing [118].
Aortic stenosis [119].
Pig Surgical model: balloon occlusionof coronary arteries [120].
Tachycardia: pacing-induced supraventricular tachycardia [121].
size greatly facilitates surgical and postsurgical procedures.
Myocardial damage in rat hearts is induced by three proce-
dures: surgical, pharmacological, or electrical.
The surgical method, ﬁrst developed by Pfeﬀer and
coworkers, consists of ligating the left coronary artery [105].
In this procedure, left thoracotomy is performed on the
anesthetized rat, and the heart is rapidly exteriorized by
gentle pressure on the right side of the thorax. The left
coronary artery is either ligated or heat cauterized between
the pulmonary artery outﬂow tract and the left atrium.
The heart is then returned to its normal position and the
thorax immediately closed. Several modiﬁcations have been
introduced to improve performance and to reduce animal
mortality, and left coronary artery ligation is the most
commonmethodusedtoinduceacutemyocardial damagein
rat and other animal models. One important modiﬁcation is
temporary occlusion followed by reperfusion, allowing ﬂow
recovery through the previously occluded coronary artery
bed.Leftcoronaryarteryligationcanthusbeusedtoevaluate
diverseparametersresulting fromeitherpermanentischemia
or ischemia/reperfusion.
Pharmacological induction of heart damage was ﬁrst
implemented by Bagdon and coworkers in 1963 and is
achieved by treatment with the beta-one adrenergic receptor
(B-AR) agonist isoproterenol [106]. Isoproterenol adminis-
tration before ischemia exerts a cardioprotective action in
rats, but at the right dose it induces cardiac myocyte necrosis
and extensive LV dilatation and hypertrophy.
Isoproterenol treatment and left coronary artery ligation
in rats are eﬃcient and reproducible methods that provide
valuable information about the underlying mechanisms
implicated in human heart disease.
The electrical method consists of generating overlapping
burns in exposed rat hearts by applying a 2-mm-tipped
soldering iron to the epicardium of the left ventricle [107].
While this is also a valid method, the degree of heart damage
produced is not consistent among laboratories, limiting the
reproducibility of the results obtained with this procedure.
4.2. Mouse Models. Against the many general advantages of
working with mice (ease of handling, low pregnancy times,
etc.), investigators choosing them as models of heart failure
must consider two important limitations: the small size of
the heart and the structural diﬀerences with respect to the
human cardiovascular system. Nonetheless, the availability
of transgenic and knockout strains and the relative ease with
whichnewgeneticmodiﬁcationscanbeintroducedmakethe
mouse oneofthemostattractivemodelsforresearch intothe
molecular basis of heart failure.
One of the most widely used models of heart failure in
mice is the left coronary artery ligation procedure, adapted
from rat. In some protocols the artery is occluded perma-
nently, butrecently proceduresfor temporary occlusionhave
been introduced to reproduce human ischemia/reperfusion
injury [108]. In this method the left anterior descending
coronary artery is occluded and then reperfused, allowing
ﬂow recovery through the previously occluded coronary
artery bed. Reperfusion is monitored visually, and the infarct
can be analyzed by histopathological techniques, and can be
documented in real time by non invasive high frequency.
The areas at risk and the infarct size are revealed by staining
with Evans blue dye and triphenyltetrazolium chloride and
are assessed by computerized planimetry. This model has
conﬁrmed the beneﬁts of reperfusion, since infarct size
was found to be signiﬁcantly lower than after permanent
occlusionof the coronary artery.
The method has been further modiﬁed to analyze
ischemic preconditioning of the heart. In this method, the
left coronary artery is repeatedly occluded to subject the
heart to several rounds of brief ischemia and reperfusion,8 Journal of Biomedicine and Biotechnology
followed by permanent occlusion. This approach has iden-
tiﬁed severalischemia-induced genesthatconfertolerance to
a subsequent ischemic event [122].
More recently, a model of myocardial infarction was
developed, in mice and rats, in which a series of cryo-
injuries is generated in the heart. This new model is yielding
promising results [109].
4.3. Large Animal Models of Heart Failure. Small animal
models have provided signiﬁcant insights into human car-
diac pathophysiology. However, rodent and human hearts
diﬀer in their architecture, heart rates, oxygen consumption,
contractility, protein expression, and even stem cell popula-
tions, and there is therefore an obvious need for models of
heart failure in large animals.
The ﬁrst large animals used to study heart failure were
dogs, in which models of myocardial infarction and serial
microembolization of the coronary artery were developed
[117]. However, the preferred large animal model of heart
damage is the pig, because the collateral coronary circulation
and arterial anatomy of pigs and humans are very similar
and infarct size can be accurately predicted [123]. Among
several models of MI in pigs, one of the most widely
used is balloon occlusion of the left anterior descending
coronary artery. In this model, a catheter is inserted through
the femoral artery, positioning an angioplasty balloon over
a guide wire at a position distal to the second largest
diagonal branch of the artery, and infarction is induced
by balloon inﬂation [120]. The similar size and cardiac
physiology of pigs and humans mean that this model oﬀers
m a j o ra d v a n t a g e so v e rm o d e l si no t h e rs p e c i e s .H o w e v e r ,t h e
method requires specialized equipment, dedicated surgical
facilities and skilled personnel, limiting the number of
laboratories able to conduct these studies.
T h er a b b i t ,m u c hl e s se x p e n s i v et h a np i g ,o ﬀers a
compromise solution.Rabbitmodelsofheart failure, includ-
ing coronary artery occlusion models [114], have major
advantages over other species. For example, the composition
of sarcomeric proteins in rabbits is similar to that in
humans, and the sarcolemmic reticulum contributes about
70% of calcium elimination. In addition, the WHHLMI
rabbit strain provides a model of spontaneous myocardial
infarction requiringnosurgicalintervention.Thismodelwas
developed by selective breeding of coronary atherosclerosis-
prone WHHL rabbits [124]. The main limitation of the
WHHLMI model is that it does not feature plaque rupture,
whereas in humans coronary plaque rupture and subsequent
intravascular thrombosis are the major causes of acute
myocardial infarction. Despite this limitation, the model is
valid for the study of atherosclerosis-related heart complica-
tions [113, 125].
An additional model of heart failure in large and small
animals is pressure overload of the left ventricle, induced
by transverse aortic constriction in mice [110]a n da o r t i c
banding in rats and rabbits. Left ventricle hypertrophy can
also be recreated by ventricular pacing in dogs [115, 118,
126], valvular stenosis in rabbits [116], and renal artery
constriction or aortic stenosis in rats, hamsters, mice, rabbits
and dogs [111, 119].
Another model of heart failure is the dilated cardiomy-
opathy. Human dilated cardiomyopathy has been modeled
in rabbits and pigs by inducing chronic tachycardia with a
pacemaker [121, 127]. Transgenic mouse models, involving
mutations that predispose to dilated cardiomyopathy, have
also proved very useful. These models have identiﬁed an
association of cytoskeletal and contractile proteins with this
pathology, and very recently a transgenic model expressing
a mutated cardiac alpha-actin gene was provided, in which
calcium sensitivity of myoﬁlaments is decreased and the
expression of calcium/calmodulin-dependent kinase IIdelta
(CaMKIIdelta) is increased [112]. Inhibition of CaMKII-
delta in these animals prevented the increase in p53 and
apoptotic cardiomyocytes and ameliorated cardiac function.
5.Conclusion
Animal models of cardiovascular disease yield important
insights into the genetic basis of human cardiovascular
diseases and provide a test bed for pharmacological and
treatments. Nonetheless, investigators need to carefully
consider their choice of model: no single method per-
fectly recreates the human disease, and there are related
considerations of cost, infrastructure and the requirement
for specialized personnel. Taking these considerations into
account, experimenters therefore need to select models that
best reproduce the aspect of disease being investigated. In
particular, when moving from bench to bedside it is essential
to test procedures in relevant models that yield highly
reproducible results, but despite these limitations, given the
range of animal models available today it will always be
possibletodeviseanappropriatestrategy,andanimalmodels
remain the best tools for advancing the understanding of the
mechanism of human cardiovascular disease.
Acknowledgments
Authors’ work has been supported by Ministerio de
Ciencia y Tecnolog´ ıa (SAF2007/63648, SAF2008/04629,
SAF2009/11749,PI10/00072), CAM (S2006/GEN-0247), FIS
(RECAVA RD06/0014/0035, PS09/00447), European Net-
work (HEALTH F2-2008-200647), Euro Salud EUS2005-
03565 and cvREMOD 091100. C. Zaragoza and C. Gomez-
Guerrero contributed equally.
References
[1] G. S. Getz and C. A. Reardon, “Diet and murine atheroscle-
rosis,” Arteriosclerosis, Thrombosis, and Vascular Biology,v o l .
26, no. 2, pp. 242–249, 2006.
[2] K. S. Meir and E. Leitersdorf, “Atherosclerosis in the
apolipoprotein E-deﬁcient mouse: a decade of progress,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no.
6, pp. 1006–1014, 2004.
[3] S. C. Whitman, “A practical approach to using mice in
atherosclerosis research,” The Clinical Biochemist Reviews,
vol. 25, pp. 81–93, 2004.
[4] S. Zadelaar, R. Kleemann, L. Verschuren et al., “Mouse
models for atherosclerosis and pharmaceutical modiﬁers,”Journal of Biomedicine and Biotechnology 9
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no.
8, pp. 1706–1721, 2007.
[ 5 ]S .I s h i b a s h i ,M .S .B r o w n ,J .L .G o l d s t e i n ,R .D .G e r a r d ,
R. E. Hammer, and J. Herz, “Hypercholesterolemia in low
density lipoprotein receptor knockout mice and its reversal
by adenovirus-mediated gene delivery,” Journal of Clinical
Investigation, vol. 92, no. 2, pp. 883–893, 1993.
[6] J. F. Bentzon and E. Falk, “Atherosclerotic lesions in mouse
and man: is it the same disease?” Current Opinion in
Lipidology, vol. 21, no. 5, pp. 434–440, 2010.
[ 7 ] J .W .K n o w l e sa n dN .M a e d a ,“ G e n e t i cm o d i ﬁ e r so f
atherosclerosis in mice,” Arteriosclerosis, Thrombosis, and
Vascular Biology, vol. 20, no. 11, pp. 2336–2345, 2000.
[8] L. Powell-Braxton,M. V´ e n i a n t ,R .D .L a t v a l ae ta l . ,“ Am o u s e
model of human familial hypercholesterolemia: markedly
elevated low density lipoprotein cholesterol levels and severe
atherosclerosison a low-fatchow diet,” Nature Medicine,v o l .
4, no. 8, pp. 934–938, 1998.
[ 9 ] M .M .V´ eniant, C. H. Zlot, R. L. Walzem et al., “Lipoprotein
clearance mechanisms in LDL receptor-deﬁcient “Apo-B48-
only” and “Apo-B100-only” mice,” Journal of Clinical Investi-
gation, vol. 102, no. 8, pp. 1559–1568, 1998.
[10] A. H. Hasty, H. Shimano, J. I. Osuga et al., “Severe hyperc-
holesterolemia, hypertriglyceridemia, and atherosclerosis in
mice lacking both leptin and the low density lipoprotein
receptor,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y ,vol.276,no.40,pp.
37402–37408, 2001.
[11] D. A. Sanan, D. L. Newland, R. Tao et al., “Low density
lipoprotein receptor-negative mice expressing human
apolipoprotein B-100 develop complex atherosclerotic
lesions on a chow diet: no accentuation by apolipoprotein,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 95, no. 8, pp. 4544–4549, 1998.
[12] S. Bonthu, D. D. Heistad, D. A. Chappell, K. G. Lamping,
and F. M. Faraci, “Atherosclerosis, vascular remodeling,
and impairment of endothelium- dependent relaxation
in genetically altered hyperlipidemic mice,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 17, no. 11, pp. 2333–
2340, 1997.
[13] J. Jawie´ n, P. Nastałek, and R. Korbut, “Mouse models
of experimental atherosclerosis,” Journal of Physiology and
Pharmacology, vol. 55, no. 3, pp. 503–517, 2004.
[14] Z. Chen, T. Fukutomi, A. C. Zago et al., “Simvastatin reduces
neointimal thickening in low-density lipoprotein receptor-
deﬁcient mice after experimental angioplastywithoutchang-
ing plasma lipids,” Circulation, vol. 106, no. 1, pp. 20–23,
2002.
[ 1 5 ]A .C .L i ,K .K .B r o w n ,M .J .S i l v e s t r e ,T .M .W i l l s o n ,W .
Palinski, and C. K. Glass, “Peroxisome proliferator-activated
receptor γ ligands inhibit development of atherosclerosis in
LDL receptor-deﬁcient mice,” Journal of Clinical Investiga-
tion, vol. 106, no. 4, pp. 523–531, 2000.
[16] N. Terasaka, A. Hiroshima, T. Koieyama et al., “T-0901317,
a synthetic liver X receptor ligand, inhibits development of
atherosclerosisin LDL receptor-deﬁcient mice,” FEBS Letters,
vol. 536, no. 1–3, pp. 6–11, 2003.
[17] S. H. Zhang, R. L. Reddick, J. A. Piedrahita, and N. Maeda,
“Spontaneous hypercholesterolemia and arterial lesions in
mice lacking apolipoprotein E,” Science, vol. 258, no. 5081,
pp. 468–471, 1992.
[18] A. S. Plump, J.D. Smith,T. Hayek et al., “Severe hypercholes-
terolemia and atherosclerosis in apolipoprotein E- deﬁcient
micecreated by homologousrecombinationinES cells,”Cell,
vol. 71, no. 2, pp. 343–353, 1992.
[19] S. H. Zhang, R. L. Reddick, B. Burkey, and N. Maeda,
“Diet-induced atherosclerosis in mice heterozygous and
homozygous for apolipoprotein E gene disruption,” Journal
of Clinical Investigation, vol. 94, no. 3, pp. 937–945, 1994.
[20] Y. Nakashima, A. S. Plump, E. W. Raines, J. L. Breslow, and
R. Ross, “ApoE-deﬁcient mice develop lesions of all phases of
atherosclerosis throughout the arterial tree,” Arteriosclerosis
and Thrombosis, vol. 14, no. 1, pp. 133–140, 1994.
[ 2 1 ]W .H u ,P .P o l i n s k y ,E .S a d o u n ,M .E .R o s e n f e l d ,a n dS .M .
Schwartz, “Atherosclerotic lesions in the common coronary
arteries of ApoE knockout mice,” Cardiovascular Pathology,
vol. 14, no. 3, pp. 120–125, 2005.
[22] R. L.Reddick, S.H.Zhang,andN. Maeda,“Atherosclerosisin
mice lacking apo E: evaluation of lesional development and
progression,” Arteriosclerosis and Thrombosis,v o l .1 4 ,n o .1 ,
pp. 141–147, 1994.
[ 2 3 ]Y .X .W a n g ,B .M a r t i n - M c N u l t y ,L .Y .H u we ta l . ,“ A n t i -
atherosclerotic eﬀect of simvastatin depends on the presence
of apolipoprotein E,” Atherosclerosis, vol. 162, no. 1, pp. 23–
31, 2002.
[24] J. Johnson, K. Carson, H. Williams et al., “Plaque rupture
after short periods of fat feeding in the apolipoprotein
E-knockout mouse: model characterization and eﬀects of
pravastatin treatment,” Circulation, vol. 111, no. 11, pp.
1422–1430, 2005.
[25] J. Gr¨ onros, J. Wikstr¨ o m ,U .B r a n d t - E l i a s s o ne ta l . ,“ E ﬀects
of rosuvastatin on cardiovascular morphology and function
in an ApoE-knockout mouse model of atherosclerosis,”
American Journal of Physiology, vol. 295, no. 5, pp. H2046–
H2053, 2008.
[ 2 6 ] Z .C h e n ,S .I s h i b a s h i ,S .P e r r e ye ta l . ,“ T r o g l i t a z o n e
inhibits atherosclerosis in apolipoprotein E-knockout mice:
pleiotropic eﬀects on CD36 expression and HDL,” Arte-
riosclerosis, Thrombosis, and Vascular Biology,v o l .2 1 ,n o .3 ,
pp. 372–377, 2001.
[27] A.C.Calkin,T.J.Allen,M.Lassila,C.Tikellis,K.A.Jandeleit-
Dahm, and M. C. Thomas, “Increased atherosclerosis fol-
lowing treatment with a dual PPAR agonist in the ApoE
knockout mouse,” Atherosclerosis, vol. 195, no. 1, pp. 17–22,
2007.
[ 2 8 ]B .T r i g a t t i ,H .R a y b u r n ,M .V i ˜ nals et al., “Inﬂuence of the
high density lipoprotein receptor SR-BI on reproductive and
cardiovascular pathophysiology,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 96,
no. 16, pp. 9322–9327, 1999.
[ 2 9 ]A .Y e s i l a l t a y ,K .D a n i e l s ,R .P a l ,M .K r i e g e r ,a n dO .K o c h e r ,
“Loss of PDZK1 causes coronary artery occlusion and
myocardial infarction in Paigen diet-fed apolipoprotein E
deﬁcient mice,” PloS one, vol. 4, no. 12, Article ID e8103,
2009.
[ 3 0 ]M .H .H o f k e r ,B .J .M .V a nV l i j m e n ,a n dL .M .H a v e k e s ,
“Transgenic mouse models to study the role of APOE in
hyperlipidemia and atherosclerosis,” Atherosclerosis, vol. 137,
no. 1, pp. 1–11, 1998.
[31] P.Lepp¨ anen,J .S.L uoma,M.H.H ofker ,L.M.H av ekes,andS.
Yl¨ a-Herttuala, “Characterization of atherosclerotic lesions in
apo E3-leiden transgenic mice,” Atherosclerosis, vol. 136, no.
1, pp. 147–152, 1998.
[32] J. W. A. Van Der Hoorn, J. W. Jukema, L. M. Havekes et al.,
“The dualPPARα/γ agonisttesaglitazarblocksprogressionof
pre-existing atherosclerosis in APOE
∗3Leiden.CETP trans-
genic mice,” British Journal of Pharmacology, vol. 156, no. 7,
pp. 1067–1075, 2009.10 Journal of Biomedicine and Biotechnology
[33] P. Reaven, S. Merat, F. Casanada, M. Sutphin, and W.
Palinski, “Eﬀect of streptozotocin-induced hyperglycemia on
lipid proﬁles, formation of advanced glycation endproducts
in lesions, and extent of atherosclerosis in LDL receptor-
deﬁcient mice,” Arteriosclerosis, Thrombosis, and Vascular
Biology, vol. 17, no. 10, pp. 2250–2256, 1997.
[34] X. Shen and K. E. Bornfeldt, “Mouse models for studies of
cardiovascular complications of type 1 diabetes,” Annals of
the New York Academy of Sciences, vol. 1103, pp. 202–217,
2007.
[ 3 5 ]T .H a y e k ,K .H u s s e i n ,M .A v i r a me ta l . ,“ M a c r o p h a g e -
foamcell formationin streptozotocin-induced diabetic mice:
stimulatory eﬀect of glucose,” Atherosclerosis, vol. 183, no. 1,
pp. 25–33, 2005.
[36] D. B. Weinreb, J. G. S. Aguinaldo, J. E. Feig, E. A. Fisher,
and Z. A. Fayad, “Non-invasive MRI of mouse models of
atherosclerosis,”NMR in Biomedicine, vol.20, no.3,pp. 256–
264, 2007.
[37] M. Aikawa, S. Sugiyama, C. C. Hill et al., “Lipid lowering
reduces oxidative stress and endothelial cell activation in
rabbit atheroma,” Circulation, vol. 106, no. 11, pp. 1390–
1396, 2002.
[38] C. Bustos, M. A. Hern´ andez-Presa, M. Ortego et al., “HMG-
CoA reductase inhibition by atorvastatin reduces neointimal
inﬂammationin a rabbitmodel ofatherosclerosis,”Journal of
the American College of Cardiology, vol. 32, no. 7, pp. 2057–
2064, 1998.
[39] R. Largo, O. S´ anchez-Pernaute, M. E. Marcos et al.,
“Chronic arthritis aggravates vascular lesions in rabbits with
atherosclerosis: a novel model of atherosclerosis associated
with chronic inﬂammation,” Arthritis and Rheumatism,v o l .
58, no. 9, pp. 2723–2734, 2008.
[40] T. Shimizu, K. Nakai, Y. Morimoto et al., “Simple rabbit
model of vulnerable atherosclerotic plaque,” Neurologia
Medico-Chirurgica, vol. 49, no. 8, pp. 327–332, 2009.
[41] G. Helft, S. G. Worthley, V. Fuster et al., “Atherosclerotic
aortic component quantiﬁcation by noninvasive magnetic
resonanceimaging:an in vivo study in rabbits,” Journal of the
American College of Cardiology, vol. 37,no. 4, pp. 1149–1154,
2001.
[42] R. G. Gerrity, R. Natarajan, J. L. Nadler, and T. Kimsey,
“Diabetes-induced accelerated atherosclerosisinswine,”Dia-
betes, vol. 50, no. 7, pp. 1654–1665, 2001.
[43] R. L. Wilensky, Y. I. Shi, E. R. Mohler et al., “Inhibition
of lipoprotein-associated phospholipase A reduces com-
plex coronary atherosclerotic plaque development,” Nature
Medicine, vol. 14, no. 10, pp. 1059–1066, 2008.
[44] J.F.Granada, G.L.Kaluza,R. L.Wilensky,B.C. Biedermann,
R. S. Schwartz, and E. Falk, “Porcine models of coronary
atherosclerosis and vulnerable plaque for imaging and inter-
ventional research,” EuroIntervention, vol. 5, no. 1, pp. 140–
148, 2009.
[45] N. Hamada, M. Miyata, H. Eto et al., “Tacrolimus-eluting
stent inhibits neointimal hyperplasia via calcineurin/NFAT
signaling in porcine coronary artery model,” Atherosclerosis,
vol. 208, no. 1, pp. 97–103, 2010.
[46] C. L. Alviar, A. Tellez, D. Wallace-Bradley et al., “Impact
of adventitial neovascularisati o no na t h e r o s c l e r o t i cp l a q u e
composition and vascular remodelling in a porcine model of
coronary atherosclerosis,” EuroIntervention,v o l .5 ,n o .8 ,p p .
981–988, 2010.
[ 4 7 ]P .B .D o b r i n ,“ B a s i cs c i e n c e :a n i m a lm o d e l so fa n e u r y s m s , ”
Annals of Vascular Surgery, vol. 13, no. 6, pp. 641–648, 1999.
[48] T.W.G.Carrell,A.Smith,andK.G.Burnand,“Experimental
techniques and models in the study of the development and
treatment of abdominal aortic aneurysm,” British Journal of
Surgery, vol. 86, no. 3, pp. 305–312, 1999.
[ 4 9 ]R .W .T h o m p s o n ,P .J .G e r a g h t y ,a n dJ .K .L e e ,“ A b d o m i n a l
aortic aneurysms: basic mechanisms and clinical implica-
tions,” Current Problems in Surgery, vol. 39, no. 2, pp. 110–
230, 2002.
[50] A. Daugherty and L. A. Cassis,“Mouse models of abdominal
aortic aneurysms,” Arteriosclerosis, Thrombosis, and Vascular
Biology, vol. 24, no. 3, pp. 429–434, 2004.
[ 5 1 ]R .A .C h a e r ,B .G .D e R u b e r t i s ,R .H y n e c e k ,K .C .K e n t ,
and P. L. Faries, “Models of abdominal aortic aneurysm:
characterization and clinical applications,” Vascular, vol. 14,
no. 6, pp. 343–352, 2006.
[52] S. Annambhotla, S. Bourgeois, X. Wang, P. H. Lin, Q. Yao,
and C. Chen, “Recent advances in molecular mechanisms
of abdominal aortic aneurysm formation,” World Journal of
Surgery, vol. 32, no. 6, pp. 976–986, 2008.
[53] K. I. Paraskevas, D. P. Mikhailidis, and D. Perrea, “Experi-
mentalmodels ofabdominalaorticaneurysms:anoverview,”
Current Pharmaceutical Design, vol. 14, no. 4, pp. 325–337,
2008.
[54] S. Anidjar, J. L. Salzmann, D. Gentric, P. Lagneau, J. P.
Camilleri, and J. B. Michel, “Elastase-induced experimental
aneurysms in rats,” Circulation, vol. 82, no. 3, pp. 973–981,
1990.
[55] S. Anidjar, P. B. Dobrin, M. Eichorst, G. P. Graham, and
G. Chejfec, “Correlation of inﬂammatory inﬁltrate with the
enlargement of experimental aortic aneurysms,” Journal of
Vascular Surgery, vol. 16, no. 2, pp. 139–147, 1992.
[ 5 6 ]T .F r e e s t o n e ,R .J .T u r n e r ,D .J .H i g m a n ,M .J .L e v e r ,a n dJ .
T. Powell, “Inﬂuence ofhypercholesterolemia and adventitial
inﬂammation on the development of aortic aneurysm in
rabbits,” Arteriosclerosis, Thrombosis, and Vascular Biology,
vol. 17, no. 1, pp. 10–17, 1997.
[57] R. Pyo, J. K. Lee, J. M. Shipley et al., “Targeted gene disrup-
tion of matrix metalloproteinase-9 (gelatinase B) suppresses
development of experimental abdominal aortic aneurysms,”
Journal of Clinical Investigation, vol. 105, no. 11, pp. 1641–
1649, 2000.
[58] E. Allaire, C. Guettier, P. Bruneval, D. Plissonnier, and J. B.
Michel, “Cell-free arterial grafts:morphologiccharacteristics
of aortic isografts, allografts, and xenografts in rats,” Journal
of Vascular Surgery, vol. 19, no. 3, pp. 446–456, 1994.
[ 5 9 ]C .M .B r o p h y ,J .E .T i l s o n ,I .M .B r a v e r m a n ,a n dM .D .
Tilson, “Age of onset, pattern of distribution, and histology
ofaneurysmdevelopmentinageneticallypredisposedmouse
model,” Journal of Vascular Surgery, vol. 8, no. 1, pp. 45–48,
1988.
[ 6 0 ]M .M a t s u s h i t a ,H .K o b a y a s h i ,K .O d a ,N .N i s h i k i m i ,T .
Sakurai,andY. Nimura,“A rabbit model ofabdominalaortic
aneurysm associated with intimal thickening,” European
Surgical Research, vol. 31, no. 4, pp. 305–313, 1999.
[ 6 1 ]N .H .F u j i w a r a ,H .J .C l o f t ,W .F .M a r x ,J .G .S h o r t ,M .E .
Jensen, and D. F. Kallmes, “Serial angiography in an elastase-
induced aneurysm model in rabbits: evidence for progressive
aneurysm enlargement after creation,” American Journal of
Neuroradiology, vol. 22, no. 4, pp. 698–703, 2001.
[62] S. D. Gertz, A. Kurgan, and D. Eisenberg, “Aneurysm of
the rabbit common carotid artery induced by periarterial
application of calcium chloride in vivo,” Journal of Clinical
Investigation, vol. 81, no. 3, pp. 649–656, 1988.Journal of Biomedicine and Biotechnology 11
[63] J. Mol´ aˇ cek, V. Tˇ reˇ ska, J. Kobr et al., “Optimization of the
model of abdominal aortic aneurysm—experiment in an
animal model,” Journal of Vascular Research,v o l .4 6 ,n o .1 ,
pp. 1–5, 2008.
[64] E. Allaire, R. Forough, M. Clowes, B. Starcher, and A. W.
Clowes, “Local overexpression of TIMP-1 prevents aortic
aneurysm degeneration and rupture in a rat model,” Journal
of Clinical Investigation, vol. 102, no. 7, pp. 1413–1420, 1998.
[65] E. Allaire, D. Hasenstab, R. D. Kenagy, B. Starcher, M. M.
Clowes, and A. W. Clowes, “Prevention of aneurysm devel-
opment and rupture by local overexpression of plasminogen
activatorinhibitor-1,”Circulation, vol.98,no.3,pp.249–255,
1998.
[66] E. Allaire, B. Muscatelli-Groux, C. Mandet et al., “Paracrine
eﬀect of vascular smooth muscle cells in the prevention of
aortic aneurysm formation,” Journal of Vascular Surgery,v o l .
36, no. 5, pp. 1018–1026, 2002.
[ 6 7 ]L .S a r d a - M a n t e l ,M .C o u t a r d ,F .R o u z e te ta l . ,“ T c - a n n e x i n -
V functional imaging of luminal thrombus activity in
abdominal aortic aneurysms,” Arteriosclerosis, Thrombosis,
and Vascular Biology, vol. 26, no. 9, pp. 2153–2159, 2006.
[68] Z.Touat,V.Ollivier,J.Daietal.,“Renewalofmuralthrombus
releases plasma markers and is involved in aortic abdominal
aneurysmevolution,”American Journalof Pathology,vol.168,
no. 3, pp. 1022–1030, 2006.
[69] J. Dai, L. Louedec, M. Philippe, J. B. Michel, and X.
Houard,“EﬀectofblockingplateletactivationwithAZD6140
on development of abdominal aortic aneurysm in a rat
aneurysmal model,” Journal of Vascular Surgery, vol. 49, no.
3, pp. 719–727, 2009.
[70] T.R.Lizarbe,C.Tar´ ın,M.G´ omezet al.,“Nitric oxide induces
the progression of abdominal aortic aneurysms through
the matrix metalloproteinaseinducer EMMPRIN,” American
Journal of Pathology, vol. 175, no. 4, pp. 1421–1430, 2009.
[ 7 1 ]R .W .T h o m p s o n ,J .A .C u r c i ,T .L .E n n i s ,D .M a o ,M .B .
Pagano, and C. T. N. Pham, “Pathophysiology of abdominal
aortic aneurysms: insights from the elastase-induced model
in mice with diﬀerent genetic backgrounds,” Annals of the
New York Academy of Sciences, vol. 1085, pp. 59–73, 2006.
[72] J. K. Lee, M. Borhani, T. L. Ennis, G. R. Upchurch, and R.
W. Thompson, “Experimental abdominal aortic aneurysms
inmicelackingexpressionofinduciblenitricoxidesynthase,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no.
9, pp. 1393–1401, 2001.
[73] E. Sho, M. Sho, H. Nanjo, K. Kawamura, H. Masuda,
and R. L. Dalman, “Hemodynamic regulation of CD34 cell
localization and diﬀerentiation in experimental aneurysms,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no.
10, pp. 1916–1921, 2004.
[74] J. L. Eliason, K. K. Hannawa, G. Ailawadi et al., “Neutrophil
depletion inhibits experimental abdominal aortic aneurysm
formation,”Circulation, vol. 112, no. 2, pp. 232–240, 2005.
[ 7 5 ]F .E .P a r o d i ,D .M a o ,T .L .E n n i s ,M .A .B a r t o l i ,a n dR .
W. Thompson, “Suppression of experimental abdominal
aortic aneurysms in mice by treatment with pyrrolidine
dithiocarbamate, an antioxidant inhibitor of nuclear factor-
κB,” Journal of Vascular Surgery, vol. 41, no. 3, pp. 479–489,
2005.
[76] E. F. Steinmetz, C. Buckley, M. L. Shames et al., “Treatment
withsimvastatinsuppressesthedevelopmentofexperimental
abdominal aortic aneurysms in normal and hypercholes-
terolemicmice,”Annals ofSurgery,vol.241,no.1,pp.92–101,
2005.
[ 7 7 ]S .J .V a nV i c k l e - C h a v e z ,W .S .T u n g ,T .S .A b s ie ta l . ,
“Temporalchangesinmouseaorticwallgeneexpressiondur-
ing the development of elastase-induced abdominal aortic
aneurysms,” Journal of Vascular Surgery,v o l .4 3 ,n o .5 ,p p .
1010–1020, 2006.
[78] M.B.P agano ,M.A.Bart oli,T .L.Ennisetal.,“ C riticalr oleof
dipeptidyl peptidase I in neutrophil recruitment during the
development of experimental abdominal aortic aneurysms,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 104, no. 8, pp. 2855–2860, 2007.
[79] J. Sun, G. K. Sukhova, M. Yang et al., “Mast cells modu-
late the pathogenesis of elastase-induced abdominal aortic
aneurysmsin mice,” Journal of Clinical Investigation,vol.117,
no. 11, pp. 3359–3368, 2007.
[80] M. B. Pagano, H. F. Zhou, T. L. Ennis et al., “Complement-
dependent neutrophil recruitment is critical for the devel-
opment of elastase-induced abdominal aortic aneurysm,”
Circulation, vol. 119, no. 13, pp. 1805–1813, 2009.
[81] A.Daugherty, M.W.Manning,andL.A.Cassis,“Angiotensin
II promotes atherosclerotic lesions and aneurysms in
apolipoprotein E-deﬁcient mice,” Journal of Clinical Investi-
gation, vol. 105, no. 11, pp. 1605–1612, 2000.
[82] L. A. Cassis, D. L. Rateri, H. Lu, and A. Daugherty, “Bone
marrow transplantationreveals that recipient AT1a receptors
arerequired toinitiateangiotensinII-induced atherosclerosis
and aneurysms,” Arteriosclerosis, Thrombosis, and Vascular
Biology, vol. 27, no. 2, pp. 380–386, 2007.
[83] D. M. Tham, B. Martin-McNulty, YI. X. Wang et al.,
“Angiotensin II is associated with activation of NF-κB-
mediated genes and downregulation of PPARs,” Physiological
Genomics, vol. 11, pp. 21–30, 2003.
[84] M. Thomas, D. Gavrila, M. L. McCormick et al., “Deletion
of p47 attenuates angiotensin II-induced abdominal aortic
aneurysm formation in apolipoprotein E-deﬁcient mice,”
Circulation, vol. 114, no. 5, pp. 404–413, 2006.
[85] K. Yoshimura, H. Aoki, Y. Ikeda et al., “Regression of
abdominal aortic aneurysm by inhibition of c-Jun N-
terminal kinase,” Nature Medicine, vol. 11, no. 12, pp. 1330–
1338, 2005.
[ 8 6 ]Y I .X .W a n g ,B .M a r t i n - M c N u l t y ,V .D aC u n h ae ta l . ,
“Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-
induced abdominal aortic aneurysm in apolipoprotein E-
deﬁcient mice by inhibiting apoptosis and proteolysis,”
Circulation, vol. 111, no. 17, pp. 2219–2226, 2005.
[87] K. Saraﬀ, F. Babamusta, L. A. Cassis, and A. Daugherty,
“Aortic dissection precedes formation of aneurysms and
atherosclerosis in angiotensin II-infused, apolipoprotein E-
deﬁcient mice,” Arteriosclerosis, Thrombosis, and Vascular
Biology, vol. 23, no. 9, pp. 1621–1626, 2003.
[88] M. Ishibashi, K. Egashira, Q. Zhao et al., “Bone
marrow-derived monocyte chemoattractant protein-
1 receptor CCR2 is critical in angiotensin II-induced
acceleration of atherosclerosis and aneurysm formation in
hypercholesterolemic mice,” Arteriosclerosis, Thrombosis, and
Vascular Biology, vol. 24, no. 11, pp. e174–178, 2004.
[89] M.W.Manning,L.A.Cassis,andA. Daugherty, “Diﬀerential
eﬀects of doxycycline, a broad-spectrum matrix metallopro-
teinase inhibitor, on angiotensin II-induced atherosclerosis
and abdominal aortic aneurysms,” Arteriosclerosis, Thrombo-
sis, and Vascular Biology, vol. 23, no. 3, pp. 483–488, 2003.
[90] G. G. Deng, B. Martin-McNulty, D. A. Sukovich et al.,
“Urokinase-type plasminogen activator plays a critical role
in angiotensin II-induced abdominal aortic aneurysm,”
Circulation Research, vol. 92, no. 5, pp. 510–517, 2003.12 Journal of Biomedicine and Biotechnology
[91] J. O. Deguchi, H. Huang, P. Libby et al., “Genetically engi-
neered resistanceforMMPcollagenasespromotesabdominal
aortic aneurysm formationin mice infused with angiotensin
II,”LaboratoryInvestigation,vol.89,no.3,pp.315–326,2009.
[ 9 2 ]V .L .K i n g ,A .Y .L i n ,F .K r i s t oe ta l . ,“ I n t e r f e r o n - γ and
the interferon-inducible chemokine CXCL10 protect against
aneurysm formation and rupture,” Circulation, vol. 119, no.
3, pp. 426–435, 2009.
[93] G. Nickenig, O. Jung, K. Strehlow et al., “Hypercholes-
terolemia is associated with enhanced angiotensin AT-
receptor expression,”American JournalofPhysiology,vol.272,
no. 6, pp. H2701–H2707, 1997.
[94] L. A. Cassis, M. Gupte, S. Thayer et al., “ANG II infu-
sion promotes abdominal aortic aneurysms independent
of increased blood pressure in hypercholesterolemic mice,”
American Journal of Physiology, vol. 296, no. 5, pp. H1660–
H1665, 2009.
[ 9 5 ]D .D a i ,Y .H .D i n g ,D .A .L e w i s ,a n dD .F .K a l l m e s ,“ Ap r o -
posed ordinalscalefor gradinghistology in elastase-induced,
saccular aneurysms,” American Journal of Neuroradiology,
vol. 27, no. 1, pp. 132–138, 2006.
[96] D. Dai, Y. H. Ding, M. A. Danielson et al., “Endovascular
treatment of experimental aneurysms with use of ﬁbroblast
transfected with replication-deﬁcient adenovirus containing
bone morphogenetic protein-13 gene,” American Journal of
Neuroradiology, vol. 29, no. 4, pp. 739–744, 2008.
[97] F. Ramirez and H. C. Dietz, “Marfan syndrome: from molec-
ular pathogenesis to clinical treatment,” Current Opinion in
Genetics and Development, vol. 17, no. 3, pp. 252–258, 2007.
[98] E. R. Neptune, P. A. Frischmeyer, D. E. Arking et al., “Dys-
regulationofTGF-β activationcontributes topathogenesisin
Marfan syndrome,” Nature Genetics, vol. 33, no. 3, pp. 407–
411, 2003.
[ 9 9 ]C .M .N g ,A .C h e n g ,L .A .M y e r se ta l . ,“ T G F - β-dependent
pathogenesis of mitral valve prolapse in a mouse model of
Marfan syndrome,” Journal of Clinical Investigation, vol. 114,
no. 11, pp. 1586–1592, 2004.
[100] J. P. Habashi, D. P. Judge, T. M. Holm et al., “Losartan, an
AT1 antagonist, prevents aortic aneurysm in a mouse model
of Marfan syndrome,” Science, vol. 312, no. 5770, pp. 117–
121, 2006.
[101] L. Carta, S. Smaldone, L. Zilberberg et al., “p38 MAPK is an
early determinant of promiscuous Smad2/3 signaling in the
aortas of ﬁbrillin-1 (Fbn1)-null mice,” Journal of Biological
Chemistry, vol. 284, no. 9, pp. 5630–5636, 2009.
[102] B.S. Brooke,J.P. Habashi,D. P.Judge, N. Patel, B.Loeys,and
H.C.Dietz,“AngiotensinIIblockadeandaortic-rootdilation
inmarfan’s syndrome,”NewEngland Journal of Medicine,v ol.
358, no. 26, pp. 2787–2795, 2008.
[103] P. Boucker, W.-P. Li, R. L. Matz et al., “LRP1 functions as
an atheroprotective integrator of TGFβ and PDGF signals in
the vascular wall: implications for Marfan syndrome,” PLoS
ONE, vol. 2, no. 5, article e448, 2007.
[104] K. Hanada, M. Vermeij, G. A. Garinis et al., “Perturbations
of vascular homeostasis and aortic valve abnormalities in
ﬁbulin-4 deﬁcient mice,” Circulation Research, vol. 100, no.
5, pp. 738–746, 2007.
[105] M. A. Pfeﬀer, J. M. Pfeﬀer, and M. C. Fishbein, “Myocardial
infarct size and ventricular function in rats,” Circulation
Research, vol. 44, no. 4, pp. 503–512, 1979.
[106] G. Zbinden and R. E. Bagdon, “Isoproterenol-induced heart
necrosis, an experimental model for the study of angina pec-
toris and myocardial infarct,” Reviews of Canadian Biology,
vol. 22, pp. 257–263, 1963.
[107] N. Adler, L. L. Camin, and P. Shulkin, “Rat model for acute
myocardial infarction: application to technetium labeled
glucoheptonate, tetracycline, and polyphosphate,” Journal of
Nuclear Medicine, vol. 17, no. 3, pp. 203–207, 1976.
[108] L. H.Michael, M. L.Entman,C. J.Hartley et al.,“Myocardial
ischemia and reperfusion: a murine model,” American Jour-
nal of Physiology, vol. 269, no. 6, pp. H2147–H2154, 1995.
[109] J. U. H. Ryu, I. L. K. Kim, S. W. Cho et al., “Implan-
tation of bone marrow mononuclear cells using injectable
ﬁbrin matrix enhances neovascularization in infarcted
myocardium,” Biomaterials, vol.26,no.3,pp. 319–326,2005.
[110] H.A.Rockman,S.P.Wachhorst,L.Mao,andJ.Ross,“ANG II
receptor blockadeprevents ventricularhypertrophy andANF
gene expression with pressure overload in mice,” American
Journal of Physiology, vol. 266, no. 6, pp. H2468–H2475,
1994.
[111] M. Shimizu, R. Tanaka, T. Fukuyama, R. Aoki, K. Orito,
and Y. Yamane, “Cardiac remodeling and angiotensin II-
forming enzyme activity of the left ventricle in hamsters
with chronic pressure overload induced by ascending aortic
stenosis,” Journal of Veterinary Medical Science, vol. 68, no. 3,
pp. 271–276, 2006.
[112] H. Toko, H. Takahashi, Y. Kayama et al., “Ca2+/calmodulin-
dependent kinase IIδ causes heart failure by accumulationof
p53 in dilated cardiomyopathy,” Circulation, vol. 122, no. 9,
pp. 891–899, 2010.
[113] M. Shiomi, S. Yamada, A. Matsukawa, H. Itabe, and T.
Ito, “Invasion of atheromatous plaques into tunica media
causes coronary outward remodeling in WHHLMI rabbits,”
Atherosclerosis, vol. 198, no. 2, pp. 287–293, 2008.
[114] G. E. Gonz´ a l e z ,I .M .S e r o p i a n ,M .L .K r i e g e re ta l . ,“ E ﬀect
of early versus late AT receptor blockade with losartan on
postmyocardialinfarctionventricularremodelinginrabbits,”
American Journal of Physiology, vol. 297, no. 1, pp. H375–
H386, 2009.
[115] K. Takeuchi, F. X. McGowan Jr., P. Glynn et al., “Glucose
transporter upregulation improves ischemic tolerance in
hypertrophied failing heart,” Circulation, vol. 98, pp. II234–
II239, 1998.
[116] D. Busseuil, Y. Shi, M. Mecteau et al., “Regression of
aortic valve stenosis by ApoA-I mimetic peptide infusions in
rabbits,” British Journal of Pharmacology, vol. 154, no. 4, pp.
765–773, 2008.
[117] S.J.Lavine,“Eﬀect ofchanges in contractility on the index of
myocardial performance in the dysfunctional left ventricle,”
Cardiovascular Ultrasound, vol. 4, article 45, 2006.
[118] M. F. M. Van Oosterhout, T. Arts, A. M. M. Muijtjens, R.
S. Reneman, and F. W. Prinzen, “Remodeling by ventric-
ular pacing in hypertrophying dog hearts,” Cardiovascular
Research, vol. 49, no. 4, pp. 771–778, 2001.
[119] M. Koide, M. Hamawaki, T. Narishige et al., “Microtubule
depolymerization normalizes in vivo myocardial contractile
function in dogs with pressure-overload left ventricular
hypertrophy,” Circulation, vol. 102, no. 9, pp. 1045–1052,
2000.
[120] Y. Suzuki, J. K. Lyons, A. C. Yeung, and F. Ikeno, “In vivo
porcine model of reperfused myocardial infarction: in situ
double staining to measure precise infarct area/area at risk,”
Catheterization and Cardiovascular Interventions, vol. 71, no.
1, pp. 100–107, 2008.
[121] F. G. Spinale, M. L. Coker, C. V. Thomas, J. D. Walker,
R. Mukherjee, and L. Hebbar, “Time-dependent changes in
matrix metalloproteinase activity and expression during the
progressionofcongestiveheart failure:relationto ventricularJournal of Biomedicine and Biotechnology 13
and myocyte function,” Circulation Research,v o l .8 2 ,n o .4 ,
pp. 482–495, 1998.
[122] M. B. West, G. Rokosh, D. Obal et al., “Cardiac myocyte-
speciﬁc expressionof inducible nitric oxide synthaseprotects
againstischemia/reperfusion injurybypreventingmitochon-
drial permeability transition,” Circulation, vol. 118, no. 19,
pp. 1970–1978, 2008.
[123] W. G. Kim, Y. C. Shin, S. W. Hwang, C. Lee, and C. Y.
Na, “Comparison of myocardial infarction with sequential
ligationof theleft anteriordescending artery andits diagonal
branch in dogs and sheep,” International Journal of Artiﬁcial
Organs, vol. 26, no. 4, pp. 351–357, 2003.
[124] M. Shiomi, T. Ito, S. Yamada, S. Kawashima, and J.
Fan, “Development of an animal model for spontaneous
myocardial infarction (WHHLMI rabbit),” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 23, no. 7, pp. 1239–
1244, 2003.
[125] Y. Kuge, N. Takai, Y. Ogawa et al., “Imaging with
radiolabelled anti-membrane type 1 matrix metallopro-
teinase (MT1-MMP) antibody: potentials for characteriz-
ing atherosclerotic plaques,” European Journal of Nuclear
Medicine and Molecular Imaging, vol. 37, pp. 2093–2104,
2010.
[126] H. Schunkert, V. J. Dzau, S. S. Tang, A. T. Hirsch, C. S.
Apstein, and B. H. Lorell, “Increased rat cardiac angiotensin
converting enzyme activity and mRNA expression in pres-
sure overload left ventricular hypertrophy. Eﬀects on coro-
nary resistance, contractility, and relaxation,” Journal of
Clinical Investigation, vol. 86, no. 6, pp. 1913–1920, 1990.
[127] D. M. Eble, J. D. Walker, A. M. Samarel, and F. G. Spinale,
“Myosin heavy chain synthesis during the progression of
chronic tachycardia induced heart failure in rabbits,” Basic
Research in Cardiology, vol. 93, no. 1, pp. 50–55, 1998.